Tatyana Sharova
Overview
Explore the profile of Tatyana Sharova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Domingues A, de Oliveira S, Tessarollo N, Lepique A, Rodrigues O, Sharova T, et al.
Mol Ther Oncol
. 2025 Mar;
33(1):200942.
PMID: 40034966
Checkpoint inhibitors have revolutionized cancer treatment, but a significant proportion of patients do not respond to these therapies, underscoring the need for alternative strategies. Although gene therapy has made substantial...
2.
Sun Y, Maggs L, Panda A, Wright S, Cicerchia A, Jenney A, et al.
Cancer Immunol Res
. 2025 Jan;
13(2):210-228.
PMID: 39785827
Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute...
3.
Chun J, Lim B, Roy S, Walsh M, Abhiraman G, Zhangxu K, et al.
bioRxiv
. 2024 Dec;
PMID: 39677740
Long-standing goals of cancer immunotherapy are to activate cytotoxic antitumor T cells across a broad range of affinities while dampening suppressive regulatory T (Treg) cell responses, but current approaches achieve...
4.
Blum S, Zlotoff D, Smith N, Kernin I, Ramesh S, Zubiri L, et al.
Nature
. 2024 Nov;
636(8041):215-223.
PMID: 39506125
Immune checkpoint inhibitors are widely used anticancer therapies that can cause morbid and potentially fatal immune-related adverse events such as immune-related myocarditis (irMyocarditis). The pathogenesis of irMyocarditis and its relationship...
5.
Mooradian M, Fintelmann F, LaSalle T, Simon J, Graur A, Muzikansky A, et al.
Nat Commun
. 2024 Aug;
15(1):7357.
PMID: 39191779
Image-guided percutaneous cryoablation is an established minimally invasive oncologic treatment. We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumor response...
6.
Thomas M, Slowikowski K, Manakongtreecheep K, Sen P, Samanta N, Tantivit J, et al.
Nat Med
. 2024 May;
30(5):1349-1362.
PMID: 38724705
Immune checkpoint inhibitor (ICI) therapy has revolutionized oncology, but treatments are limited by immune-related adverse events, including checkpoint inhibitor colitis (irColitis). Little is understood about the pathogenic mechanisms driving irColitis,...
7.
Revach O, Cicerchia A, Shorer O, Petrova B, Anderson S, Park J, et al.
bioRxiv
. 2024 Feb;
PMID: 38405985
A central problem in cancer immunotherapy with immune checkpoint blockade (ICB) is the development of resistance, which affects 50% of patients with metastatic melanoma. T cell exhaustion, resulting from chronic...
8.
Dedeilia A, Lwin T, Li S, Tarantino G, Tunsiricharoengul S, Lawless A, et al.
Ann Surg Oncol
. 2023 Dec;
31(4):2713-2726.
PMID: 38158497
Background: In the current era of effective adjuvant therapies and de-escalation of surgery, distinguishing which patients with high-risk stage II melanoma are at increased risk of recurrence after excision of...
9.
Blum S, Zlotoff D, Smith N, Kernin I, Ramesh S, Zubiri L, et al.
bioRxiv
. 2023 Oct;
PMID: 37790460
Immune checkpoint inhibitors (ICIs) are widely used anti-cancer therapies that can cause morbid and potentially fatal immune-related adverse events (irAEs). ICI-related myocarditis (irMyocarditis) is uncommon but has the highest mortality...
10.
Taylor M, Wu C, Fridy P, Zhang S, Senussi Y, Wolters J, et al.
Cancer Discov
. 2023 Sep;
13(12):2532-2547.
PMID: 37698949
Significance: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and...